IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab
Giorgia Marisi,1 Emanuela Scarpi,2 Alessandro Passardi,3 Oriana Nanni,2 Flavia Pagan,2 Martina Valgiusti,3 Andrea Casadei Gardini,3 Luca Maria Neri,4 Giovanni Luca Frassineti,3 Dino Amadori,3 Paola Ulivi1 1Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRS...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-11-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/il-8-and-thrombospondin-1-as-prognostic-markers-in-patients-with-metas-peer-reviewed-article-CMAR |
| _version_ | 1818013774775320576 |
|---|---|
| author | Marisi G Scarpi E Passardi A Nanni O Pagan F Valgiusti M Casadei Gardini A Neri LM Frassineti GL Amadori D Ulivi P |
| author_facet | Marisi G Scarpi E Passardi A Nanni O Pagan F Valgiusti M Casadei Gardini A Neri LM Frassineti GL Amadori D Ulivi P |
| author_sort | Marisi G |
| collection | DOAJ |
| description | Giorgia Marisi,1 Emanuela Scarpi,2 Alessandro Passardi,3 Oriana Nanni,2 Flavia Pagan,2 Martina Valgiusti,3 Andrea Casadei Gardini,3 Luca Maria Neri,4 Giovanni Luca Frassineti,3 Dino Amadori,3 Paola Ulivi1 1Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy; 2Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy; 3Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy; 4Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara 44100, Italy Purpose: Bevacizumab (B) plus chemotherapy (CT) is a common choice for first-line treatment of metastatic colorectal cancer. Molecular predictors of B efficacy have still not been identified. We analyzed the role of 22 angiogenesis-associated proteins in patient outcome.Patients and methods: Serum samples collected at baseline and at the first clinical evaluation were available for 58 patients enrolled in the randomized multicenter ITACa trial and who received CT+ B. Serum protein levels were determined using multiplex ELISA.Results: Patients with baseline ≥145 pg/mL IL-8 showed shorter median progression-free survival and overall survival (OS) than those with lower levels (6.5 vs 6. 12.6 months; HR 7.39, P<0.0001 and 8.7 vs 28.8 months, HR 7.68, P<0.001, respectively). Moreover, patients with baseline thrombospondin-1 levels ≥12,000 ng/mL had a better median OS than those with lower levels (34.5 vs 13.1 months, HR 0.43, P=0.007). Patients with a ≥20% reduction in IL-8 levels from baseline to first clinical evaluation showed a better progression-free survival and OS than the others (HR 0.41, P=0.005 and HR 0.43, P=0.007, respectively).Conclusion: Baseline IL-8 and thrombospondin-1 levels and reduced IL-8 during B treatment could represent potential prognostic markers in metastatic colorectal cancer. Keywords: serum biomarkers, targeted therapy, IL-8, angiogenesis, chemotherapy |
| first_indexed | 2024-04-14T06:37:24Z |
| format | Article |
| id | doaj.art-7f2a2d90860442eaa198a2b9a6c36325 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-04-14T06:37:24Z |
| publishDate | 2018-11-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-7f2a2d90860442eaa198a2b9a6c363252022-12-22T02:07:26ZengDove Medical PressCancer Management and Research1179-13222018-11-01Volume 105659566642292IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumabMarisi GScarpi EPassardi ANanni OPagan FValgiusti MCasadei Gardini ANeri LMFrassineti GLAmadori DUlivi PGiorgia Marisi,1 Emanuela Scarpi,2 Alessandro Passardi,3 Oriana Nanni,2 Flavia Pagan,2 Martina Valgiusti,3 Andrea Casadei Gardini,3 Luca Maria Neri,4 Giovanni Luca Frassineti,3 Dino Amadori,3 Paola Ulivi1 1Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy; 2Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy; 3Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy; 4Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara 44100, Italy Purpose: Bevacizumab (B) plus chemotherapy (CT) is a common choice for first-line treatment of metastatic colorectal cancer. Molecular predictors of B efficacy have still not been identified. We analyzed the role of 22 angiogenesis-associated proteins in patient outcome.Patients and methods: Serum samples collected at baseline and at the first clinical evaluation were available for 58 patients enrolled in the randomized multicenter ITACa trial and who received CT+ B. Serum protein levels were determined using multiplex ELISA.Results: Patients with baseline ≥145 pg/mL IL-8 showed shorter median progression-free survival and overall survival (OS) than those with lower levels (6.5 vs 6. 12.6 months; HR 7.39, P<0.0001 and 8.7 vs 28.8 months, HR 7.68, P<0.001, respectively). Moreover, patients with baseline thrombospondin-1 levels ≥12,000 ng/mL had a better median OS than those with lower levels (34.5 vs 13.1 months, HR 0.43, P=0.007). Patients with a ≥20% reduction in IL-8 levels from baseline to first clinical evaluation showed a better progression-free survival and OS than the others (HR 0.41, P=0.005 and HR 0.43, P=0.007, respectively).Conclusion: Baseline IL-8 and thrombospondin-1 levels and reduced IL-8 during B treatment could represent potential prognostic markers in metastatic colorectal cancer. Keywords: serum biomarkers, targeted therapy, IL-8, angiogenesis, chemotherapyhttps://www.dovepress.com/il-8-and-thrombospondin-1-as-prognostic-markers-in-patients-with-metas-peer-reviewed-article-CMARserum biomarkerstargeted therapyIL-8angiogenesischemotherapy |
| spellingShingle | Marisi G Scarpi E Passardi A Nanni O Pagan F Valgiusti M Casadei Gardini A Neri LM Frassineti GL Amadori D Ulivi P IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab Cancer Management and Research serum biomarkers targeted therapy IL-8 angiogenesis chemotherapy |
| title | IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab |
| title_full | IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab |
| title_fullStr | IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab |
| title_full_unstemmed | IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab |
| title_short | IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab |
| title_sort | il 8 and thrombospondin 1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab |
| topic | serum biomarkers targeted therapy IL-8 angiogenesis chemotherapy |
| url | https://www.dovepress.com/il-8-and-thrombospondin-1-as-prognostic-markers-in-patients-with-metas-peer-reviewed-article-CMAR |
| work_keys_str_mv | AT marisig il8andthrombospondin1asprognosticmarkersinpatientswithmetastaticcolorectalcancerreceivingbevacizumab AT scarpie il8andthrombospondin1asprognosticmarkersinpatientswithmetastaticcolorectalcancerreceivingbevacizumab AT passardia il8andthrombospondin1asprognosticmarkersinpatientswithmetastaticcolorectalcancerreceivingbevacizumab AT nannio il8andthrombospondin1asprognosticmarkersinpatientswithmetastaticcolorectalcancerreceivingbevacizumab AT paganf il8andthrombospondin1asprognosticmarkersinpatientswithmetastaticcolorectalcancerreceivingbevacizumab AT valgiustim il8andthrombospondin1asprognosticmarkersinpatientswithmetastaticcolorectalcancerreceivingbevacizumab AT casadeigardinia il8andthrombospondin1asprognosticmarkersinpatientswithmetastaticcolorectalcancerreceivingbevacizumab AT nerilm il8andthrombospondin1asprognosticmarkersinpatientswithmetastaticcolorectalcancerreceivingbevacizumab AT frassinetigl il8andthrombospondin1asprognosticmarkersinpatientswithmetastaticcolorectalcancerreceivingbevacizumab AT amadorid il8andthrombospondin1asprognosticmarkersinpatientswithmetastaticcolorectalcancerreceivingbevacizumab AT ulivip il8andthrombospondin1asprognosticmarkersinpatientswithmetastaticcolorectalcancerreceivingbevacizumab |